# US 2023/0265406 A1 · Recombinant sialidases with reduced protease sensitivity, sialidase fusion proteins, and methods of using the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0265406 A1
- Document ID: US20230265406A1
- Status: Published application
- Kind: A1
- Application number: 18/003,234
- Filed: 2021-07-02
- Published: 2023-08-24
- Earliest claimed: 2020-07-03
- Assignees: Palleon Pharmaceuticals Inc.
- Applicants: Palleon Pharmaceuticals Inc.
- Inventors: Li Peng; Sandip A. Shelke; Lizhi Cao
- Web page: https://patentgrep.com/patent/US20230265406A1

## CPC

- C12N 9/2402: {hydrolysing O- and S- glycosyl compounds (3.2.1)}
- A61P 35/00: Antineoplastic agents
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- C07K 16/2887: {against CD20}
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- C07K 16/32: against translation products of oncogenes
- C07K 16/40: against enzymes
- C12Y 302/01018: Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES

## Abstract

The invention relates generally to recombinant sialidases (for example, recombinant sialidases having reduced protease sensitivity), recombinant fusion proteins, and antibody conjugates, and their use in the treatment of cancer.

## Claims

### Claim 1

A recombinant mutant sialidase enzyme (e.g., human sialidase enzyme), wherein the sialidase comprises a mutation that increases resistance to cleavage by a protease.

### Claim 2 (depends on 1)

The enzyme of claim 1, wherein incubation of the sialidase with the protease results in less than 50% (e.g., less than 40%, less than 30%, less than 10%, less than 5%, less than 3%, less than 1%, or less than 0.5%) of the proteolytic cleavage of a corresponding wild-type sialidase when incubated with the protease under the same conditions.

### Claim 3 (depends on 1, 2)

The enzyme of claim 1 or claim 2, wherein the protease is trypsin.

### Claim 4 (depends on 1, 2, 3)

The enzyme of any one of claims 1-3, wherein the sialidase comprises:
(a) a substitution of an alanine residue at a position corresponding to position 213 of wild-type human Neu2 (A213);
(b) a substitution of a leucine residue at a position corresponding to position 240 of wild-type human Neu2 (L240);
(c) a substitution of an arginine residue at a position corresponding to position 241 of wild-type human Neu2 (R241);
(d) a substitution of an alanine residue at a position corresponding to position 242 of wild-type human Neu2 (A242);
(e) a substitution of an arginine residue at a position corresponding to position 243 of wild-type human Neu2 (R243);
(f) a substitution of a valine residue at a position corresponding to position 244 of wild-type human Neu2 (V244);
(g) a substitution of a serine residue at a position corresponding to position 258 of wild-type human Neu2 (S258);
(h) a substitution of a leucine residue at a position corresponding to position 260 of wild-type human Neu2 (L260);
(i) a substitution of a valine residue at a position corresponding to position 265 of wild-type human Neu2 (V265);
or a combination of any of the foregoing substitutions.

### Claim 5 (depends on 4)

The enzyme of claim 4, wherein, in the sialidase:
(a) the alanine residue at a position corresponding to position 213 of wild-type human Neu2 is substituted by cysteine (A213C), asparagine (A213N), serine (A213S), or threonine (A213T);
(b) the leucine residue at a position corresponding to position 240 of wild-type human Neu2 (L240) is substituted by aspartic acid (L240D), asparagine (L240N), or tyrosine (L240Y);
(c) the arginine residue at a position corresponding to position 241 of wild-type human Neu2 (R241) is substituted by alanine (R241A), aspartic acid (R241D), leucine (R241L), glutamine (R241Q). or tyrosine (R241Y);
(d) the alanine residue at a position corresponding to position 242 of wild-type human Neu2 (A242) is substituted by cysteine (A242C), phenylalanine (A242F), glycine (A242G), histidine (A242H), isoleucine (A242I), lysine (A242K), leucine (A242L), methionine (A242M), asparagine (A242N), glutamine (A242Q), arginine (A242R), serine (A242S), valine (A242V), tryptophan (A242W), or tyrosine (A242Y);
(e) the valine residue at a position corresponding to position 244 of wild-type human Neu2 (V244) is substituted by isoleucine (V244I), lysine (V244K), or proline (V244P);
(f) the serine residue at a position corresponding to position 258 of wild-type human Neu2 (S258) is substituted by cysteine (S258C);
(g) the leucine residue at a position corresponding to position 260 of wild-type human Neu2 (L260) is substituted by aspartic acid (L260D), phenylalanine (L260F), glutamine (L260Q), or threonine (L260T);
(h) the valine residue at a position corresponding to position 265 of wild-type human Neu2 (V265) is substituted by phenylalanine (V265F);
or a combination of any of the foregoing substitutions.

### Claim 6 (depends on 5)

The enzyme of claim 5, wherein, the sialidase comprises a combination of substitutions as set forth in TABLE 2.

### Claim 7

A recombinant mutant human sialidase enzyme, wherein the sialidase comprises:
(a) a substitution of a proline residue at a position corresponding to position 5 of wild-type human Neu2 (P5);
(b) a substitution of a lysine residue at a position corresponding to position 9 of wild-type human Neu2 (K9);
(c) a substitution of an alanine residue at a position corresponding to position 42 of wild-type human Neu2 (A42);
(d) a substitution of a lysine residue at a position corresponding to position 44 of wild-type human Neu2 (K44);
(e) a substitution of a lysine residue at a position corresponding to position 45 of wild-type human Neu2 (K45);
(f) a substitution of a leucine residue at a position corresponding to position 54 of wild-type human Neu2 (L54);
(g) a substitution of a proline residue at a position corresponding to position 62 of wild-type human Neu2 (P62);
(h) a substitution of a glutamine residue at a position corresponding to position 69 of wild-type human Neu2 (Q69);
(i) a substitution of an arginine residue at a position corresponding to position 78 of wild-type human Neu2 (R78);
(j) a substitution of an aspartic acid residue at a position corresponding to position 80 of wild-type human Neu2 (D80);
(k) a substitution of an alanine residue at a position corresponding to position 93 of wild-type human Neu2 (A93);
(l) a substitution of a glycine residue at a position corresponding to position 107 of wild-type human Neu2 (G107);
(m) a substitution of a glutamine residue at a position corresponding to position 108 of wild-type human Neu2 (Q108);
(n) a substitution of a glutamine residue at a position corresponding to position 112 of wild-type human Neu2 (Q112);
(o) a substitution of a cysteine residue at a position corresponding to position 125 of wild-type human Neu2 (C125);
(p) a substitution of a glutamine residue at a position corresponding to position 126 of wild-type human Neu2 (Q126);
(q) a substitution of an alanine residue at a position corresponding to position 150 of wild-type human Neu2 (A150);
(r) a substitution of a cysteine residue at a position corresponding to position 164 of wild-type human Neu2 (C164);
(s) a substitution of an arginine residue at a position corresponding to position 170 of wild-type human Neu2 (R170);
(t) a substitution of an alanine residue at a position corresponding to position 171 of wild-type human Neu2 (A171);
(u) a substitution of a glutamine residue at a position corresponding to position 188 of wild-type human Neu2 (Q188);
(v) a substitution of an arginine residue at a position corresponding to position 189 of wild-type human Neu2 (R189);
(w) a substitution of an alanine residue at a position corresponding to position 213 of wild-type human Neu2 (A213);
(x) a substitution of a leucine residue at a position corresponding to position 217 of wild-type human Neu2 (L217);
(y) a substitution of a glutamic acid residue at a position corresponding to position 225 of wild-type human Neu2 (E225);
(z) a substitution of a histidine residue at a position corresponding to position 239 of wild-type human Neu2 (H239);
(aa) a substitution of a leucine residue at a position corresponding to position 240 of wild-type human Neu2 (L240);
(bb) a substitution of an arginine residue at a position corresponding to position 241 of wild-type human Neu2 (R241);
(cc) a substitution of an alanine residue at a position corresponding to position 242 of wild-type human Neu2 (A242);
(dd) a substitution of a valine residue at a position corresponding to position 244 of wild-type human Neu2 (V244);
(ee) a substitution of a threonine residue at a position corresponding to position 249 of wild-type human Neu2 (T249);
(ff) a substitution of an aspartic acid residue at a position corresponding to position 251 of wild-type human Neu2 (D251);
(gg) a substitution of a glutamic acid residue at a position corresponding to position 257 of wild-type human Neu2 (E257);
(hh) a substitution of a serine residue at a position corresponding to position 258 of wild-type human Neu2 (S258);
(ii) a substitution of a leucine residue at a position corresponding to position 260 of wild-type human Neu2 (L260);
(jj) a substitution of a valine residue at a position corresponding to position 265 of wild-type human Neu2 (V265);
(kk) a substitution of a glutamine residue at a position corresponding to position 270 of wild-type human Neu2 (Q270);
(ll) a substitution of a tryptophan residue at a position corresponding to position 292 of wild-type human Neu2 (W292);
(mm) a substitution of a serine residue at a position corresponding to position 301 of wild-type human Neu2 (S301);
(nn) a substitution of a tryptophan residue at a position corresponding to position 302 of wild-type human Neu2 (W302);
(oo) a substitution of a valine residue at a position corresponding to position 363 of wild-type human Neu2 (V363); or
(pp) a substitution of a leucine residue at a position corresponding to position 365 of wild-type human Neu2 (L365);
or a combination of any of the foregoing substitutions.

### Claim 8

A recombinant mutant human sialidase enzyme, wherein the sialidase comprises:
(a) a substitution of a proline residue at a position corresponding to position 5 of wild-type human Neu2 (P5);
(b) a substitution of a lysine residue at a position corresponding to position 9 of wild-type human Neu2 (K9);
(c) a substitution of a lysine residue at a position corresponding to position 44 of wild-type human Neu2 (K44);
(d) a substitution of a lysine residue at a position corresponding to position 45 of wild-type human Neu2 (K45);
(e) a substitution of a leucine residue at a position corresponding to position 54 of wild-type human Neu2 (L54);
(f) a substitution of a proline residue at a position corresponding to position 62 of wild-type human Neu2 (P62);
(g) a substitution of a glutamine residue at a position corresponding to position 69 of wild-type human Neu2 (Q69);
(h) a substitution of an arginine residue at a position corresponding to position 78 of wild-type human Neu2 (R78);
(i) a substitution of an aspartic acid residue at a position corresponding to position 80 of wild-type human Neu2 (D80);
(j) a substitution of an alanine residue at a position corresponding to position 93 of wild-type human Neu2 (A93);
(k) a substitution of a glycine residue at a position corresponding to position 107 of wild-type human Neu2 (G107);
(l) a substitution of a glutamine residue at a position corresponding to position 108 of wild-type human Neu2 (Q108);
(m) a substitution of a glutamine residue at a position corresponding to position 112 of wild-type human Neu2 (Q112);
(n) a substitution of a cysteine residue at a position corresponding to position 125 of wild-type human Neu2 (C125);
(o) a substitution of a glutamine residue at a position corresponding to position 126 of wild-type human Neu2 (Q126);
(p) a substitution of an alanine residue at a position corresponding to position 150 of wild-type human Neu2 (A150);
(q) a substitution of a cysteine residue at a position corresponding to position 164 of wild-type human Neu2 (C164);
(r) a substitution of an arginine residue at a position corresponding to position 170 of wild-type human Neu2 (R170);
(s) a substitution of an alanine residue at a position corresponding to position 171 of wild-type human Neu2 (A171);
(t) a substitution of a glutamine residue at a position corresponding to position 188 of wild-type human Neu2 (Q188);
(u) a substitution of an arginine residue at a position corresponding to position 189 of wild-type human Neu2 (R189);
(v) a substitution of an alanine residue at a position corresponding to position 213 of wild-type human Neu2 (A213);
(w) a substitution of a leucine residue at a position corresponding to position 217 of wild-type human Neu2 (L217);
(x) a substitution of a glutamic acid residue at a position corresponding to position 225 of wild-type human Neu2 (E225);
(y) a substitution of a histidine residue at a position corresponding to position 239 of wild-type human Neu2 (H239);
(z) a substitution of a leucine residue at a position corresponding to position 240 of wild-type human Neu2 (L240);
(aa) a substitution of an arginine residue at a position corresponding to position 241 of wild-type human Neu2 (R241);
(bb) a substitution of an alanine residue at a position corresponding to position 242 of wild-type human Neu2 (A242);
(cc) a substitution of a valine residue at a position corresponding to position 244 of wild-type human Neu2 (V244);
(dd) a substitution of a threonine residue at a position corresponding to position 249 of wild-type human Neu2 (T249);
(ee) a substitution of an aspartic acid residue at a position corresponding to position 251 of wild-type human Neu2 (D251);
(ff) a substitution of a glutamic acid residue at a position corresponding to position 257 of wild-type human Neu2 (E257);
(gg) a substitution of a serine residue at a position corresponding to position 258 of wild-type human Neu2 (S258);
(hh) a substitution of a leucine residue at a position corresponding to position 260 of wild-type human Neu2 (L260);
(ii) a substitution of a valine residue at a position corresponding to position 265 of wild-type human Neu2 (V265);
(jj) a substitution of a glutamine residue at a position corresponding to position 270 of wild-type human Neu2 (Q270);
(kk) a substitution of a tryptophan residue at a position corresponding to position 292 of wild-type human Neu2 (W292);
(ll) a substitution of a serine residue at a position corresponding to position 301 of wild-type human Neu2 (S301);
(mm) a substitution of a tryptophan residue at a position corresponding to position 302 of wild-type human Neu2 (W302);
(nn) a substitution of a valine residue at a position corresponding to position 363 of wild-type human Neu2 (V363); or
(oo) a substitution of a leucine residue at a position corresponding to position 365 of wild-type human Neu2 (L365);
or a combination of any of the foregoing substitutions.

### Claim 9 (depends on 7, 8)

The enzyme of claim 7 or 8, wherein the sialidase comprises a substitution of K9, A42, P62, A93, Q126, A242, Q270, S301, W302, V363, or L365, or a combination of any of the foregoing substitutions.

### Claim 10 (depends on 7, 8)

The enzyme of claim 7 or 8, wherein the sialidase comprises a substitution of K9, P62, A93, Q126, A242, Q270, S301, W302, V363, or L365, or a combination of any of the foregoing substitutions.

### Claim 11 (depends on 7, 8, 9, 10)

The enzyme of any one of claims 7-10, wherein, in the sialidase:
(a) the proline residue at a position corresponding to position 5 of wild-type human Neu2 is substituted by histidine (P5H);
(b) the lysine residue at a position corresponding to position 9 of wild-type human Neu2 is substituted by aspartic acid (K9D);
(c) the alanine residue at a position corresponding to position 42 of wild-type human Neu2 is substituted by arginine (A42R);
(d) the lysine residue at a position corresponding to position 44 of wild-type human Neu2 is substituted by arginine (K44R) or glutamic acid (K44E);
(e) the lysine residue at a position corresponding to position 45 of wild-type human Neu2 is substituted by alanine (K45A), arginine (K45R), or glutamic acid (K45E);
(f) the leucine residue at a position corresponding to position 54 of wild-type human Neu2 is substituted by methionine (L54M);
(g) the proline residue at a position corresponding to position 62 of wild-type human Neu2 is substituted by asparagine (P62N), aspartic acid (P62D), histidine (P62H), glutamic acid (P62E), glycine (P62G), serine (P62S), or threonine (P62T);
(h) the glutamine residue at a position corresponding to position 69 of wild-type human Neu2 is substituted by histidine (Q69H);
(i) the arginine residue at a position corresponding to position 78 of wild-type human Neu2 is substituted by lysine (R78K);
(j) the aspartic acid residue at a position corresponding to position 80 of wild-type human Neu2 is substituted by proline (D80P);
(k) the alanine residue at a position corresponding to position 93 of wild-type human Neu2 is substituted by glutamic acid (A93E) or lysine (A93K);
(l) the glycine residue at a position corresponding to position 107 of wild-type human Neu2 is substituted by aspartic acid (G107D);
(m) the glutamine residue at a position corresponding to position 108 of wild-type human Neu2 is substituted by histidine (Q108H);
(n) the glutamine residue at a position corresponding to position 112 of wild-type human Neu2 is substituted by arginine (Q112R) or lysine (Q112K);
(o) the cysteine residue at a position corresponding to position 125 of wild-type human Neu2 is substituted by leucine (C125L);
(p) the glutamine residue at a position corresponding to position 126 of wild-type human Neu2 is substituted by leucine (Q126L), glutamic acid (Q126E), phenylalanine (Q126F), histidine (Q126H), isoleucine (Q126I), or tyrosine (Q126Y);
(q) the alanine residue at a position corresponding to position 150 of wild-type human Neu2 is substituted by valine (A150V);
(r) the cysteine residue at a position corresponding to position 164 of wild-type human Neu2 is substituted by glycine (C164G);
(s) the arginine residue at a position corresponding to position 170 of wild-type human Neu2 is substituted by proline (R170P);
(t) the alanine residue at a position corresponding to position 171 of wild-type human Neu2 is substituted by glycine (A171G);
(u) the glutamine residue at a position corresponding to position 188 of wild-type human Neu2 is substituted by proline (Q188P);
(v) the arginine residue at a position corresponding to position 189 of wild-type human Neu2 is substituted by proline (R189P);
(w) the alanine residue at a position corresponding to position 213 of wild-type human Neu2 is substituted by cysteine (A213C), asparagine (A213N), serine (A213S) or threonine (A213 T);
(x) the leucine residue at a position corresponding to position 217 of wild-type human Neu2 is substituted by alanine (L217A) or valine (L217V);
(y) the glutamic acid residue at a position corresponding to position 225 of wild-type human Neu2 is substituted by proline (E225P);
(z) the histidine residue at a position corresponding to position 239 of wild-type human Neu2 is substituted by proline (H239P);
(aa) the leucine residue at a position corresponding to position 240 of wild-type human Neu2 is substituted by aspartic acid (L240D), asparagine (L240N), or tyrosine (L240Y);
(bb) the arginine residue at a position corresponding to position 241 of wild-type human Neu2 is substituted by alanine (R241A), aspartic acid (R241D), leucine (R241L), glutamine (R241Q). or tyrosine (R241Y);
(cc) the alanine residue at a position corresponding to position 242 of wild-type human Neu2 is substituted by cysteine (A242C), phenylalanine (A242F), glycine (A242G), histidine (A242H), isoleucine (A242I), lysine (A242K), leucine (A242L), methionine (A242M), asparagine (A242N), glutamine (A242Q), arginine (A242R), serine (A242S), valine (A242V), tryptophan (A242W), or tyrosine (A242Y);
(dd) the valine residue at a position corresponding to position 244 of wild-type human Neu2 is substituted by isoleucine (V244I) or proline (V244P);
(ee) the threonine residue at a position corresponding to position 249 of wild-type human Neu2 is substituted by alanine (T249A);
(ff) the aspartic acid residue at a position corresponding to position 251 of wild-type human Neu2 is substituted by glycine (D251G);
(gg) the glutamic acid residue at a position corresponding to position 257 of wild-type human Neu2 is substituted by proline (E257P);
(hh) the serine residue at a position corresponding to position 258 is substituted by cysteine (S258C);
(ii) the leucine residue at a position corresponding to position 260 of wild-type human Neu2 is substituted by aspartic acid (L260D), phenylalanine (L260F), glutamine (L260Q), or threonine (L260T);
(jj) the valine residue at a position corresponding to position 265 of wild-type human Neu2 is substituted by phenylalanine (V265F);
(kk) the glutamine residue at a position corresponding to position 270 of wild-type human Neu2 is substituted by alanine (Q270A), histidine (Q270H), phenylalanine (Q270F), proline (Q270P), serine (Q270S), or threonine (Q270T);
(ll) the tryptophan residue at a position corresponding to position 292 of wild-type human Neu2 is substituted by arginine (W292R);
(mm) the serine residue at a position corresponding to position 301 of wild-type human Neu2 is substituted by alanine (S301A), aspartic acid (S301D), glutamic acid (S301E), phenylalanine (S301F), histidine (S301H), lysine (S301K), leucine (S301L), methionine (S301M), asparagine (S301N), proline (S301P), glutamine (S301Q), arginine (S301R), threonine (S301T), valine (S301V), tryptophan (S301W), or tyrosine (S301Y);
(nn) the tryptophan residue at a position corresponding to position 302 of wild-type human Neu2 is substituted by alanine (W302A), aspartic acid (W302D), phenylalanine (W302F), glycine (W302G), histidine (W302H), isoleucine (W302I), lysine (W302K), leucine (W302L), methionine (W302M), asparagine (W302N), proline (W302P), glutamine (W302Q), arginine (W302R), serine (W302S), threonine (W302T), valine (W302V), or tyrosine (W302Y);
(oo) the valine residue at a position corresponding to position 363 of wild-type human Neu2 is substituted by arginine (V363R); or
(pp) the leucine residue at a position corresponding to position 365 of wild-type human Neu2 is substituted by glutamine (L365Q), histidine (L365H), isoleucine (L365I), lysine (L365K) or serine (L365S);
or the sialidase comprises a combination of any of the foregoing substitutions.

### Claim 12 (depends on 7, 8, 9, 10)

The enzyme of any one of claims 7-10, wherein, in the sialidase:
(a) the proline residue at a position corresponding to position 5 of wild-type human Neu2 is substituted by histidine (P5H);
(b) the lysine residue at a position corresponding to position 9 of wild-type human Neu2 is substituted by aspartic acid (K9D);
(c) the lysine residue at a position corresponding to position 44 of wild-type human Neu2 is substituted by arginine (K44R) or glutamic acid (K44E);
(d) the lysine residue at a position corresponding to position 45 of wild-type human Neu2 is substituted by alanine (K45A), arginine (K45R), or glutamic acid (K45E);
(e) the leucine residue at a position corresponding to position 54 of wild-type human Neu2 is substituted by methionine (L54M);
(f) the proline residue at a position corresponding to position 62 of wild-type human Neu2 is substituted by asparagine (P62N), aspartic acid (P62D), histidine (P62H), glutamic acid (P62E), glycine (P62G), serine (P62S), or threonine (P62T);
(g) the glutamine residue at a position corresponding to position 69 of wild-type human Neu2 is substituted by histidine (Q69H);
(h) the arginine residue at a position corresponding to position 78 of wild-type human Neu2 is substituted by lysine (R78K);
(i) the aspartic acid residue at a position corresponding to position 80 of wild-type human Neu2 is substituted by proline (D80P);
(j) the alanine residue at a position corresponding to position 93 of wild-type human Neu2 is substituted by glutamic acid (A93E) or lysine (A93K);
(k) the glycine residue at a position corresponding to position 107 of wild-type human Neu2 is substituted by aspartic acid (G107D);
(l) the glutamine residue at a position corresponding to position 108 of wild-type human Neu2 is substituted by histidine (Q108H);
(m) the glutamine residue at a position corresponding to position 112 of wild-type human Neu2 is substituted by arginine (Q112R) or lysine (Q112K);
(n) the cysteine residue at a position corresponding to position 125 of wild-type human Neu2 is substituted by leucine (C125L);
(o) the glutamine residue at a position corresponding to position 126 of wild-type human Neu2 is substituted by leucine (Q126L), glutamic acid (Q126E), phenylalanine (Q126F), histidine (Q126H), isoleucine (Q126I), or tyrosine (Q126Y);
(p) the alanine residue at a position corresponding to position 150 of wild-type human Neu2 is substituted by valine (A150V);
(q) the cysteine residue at a position corresponding to position 164 of wild-type human Neu2 is substituted by glycine (C164G);
(r) the arginine residue at a position corresponding to position 170 of wild-type human Neu2 is substituted by proline (R170P);
(s) the alanine residue at a position corresponding to position 171 of wild-type human Neu2 is substituted by glycine (A171G);
(t) the glutamine residue at a position corresponding to position 188 of wild-type human Neu2 is substituted by proline (Q188P);
(u) the arginine residue at a position corresponding to position 189 of wild-type human Neu2 is substituted by proline (R189P);
(v) the alanine residue at a position corresponding to position 213 of wild-type human Neu2 is substituted by cysteine (A213C), asparagine (A213N), serine (A213S) or threonine (A213 T);
(w) the leucine residue at a position corresponding to position 217 of wild-type human Neu2 is substituted by alanine (L217A) or valine (L217V);
(x) the glutamic acid residue at a position corresponding to position 225 of wild-type human Neu2 is substituted by proline (E225P);
(y) the histidine residue at a position corresponding to position 239 of wild-type human Neu2 is substituted by proline (H239P);
(z) the leucine residue at a position corresponding to position 240 of wild-type human Neu2 is substituted by aspartic acid (L240D), asparagine (L240N), or tyrosine (L240Y);
(aa) the arginine residue at a position corresponding to position 241 of wild-type human Neu2 is substituted by alanine (R241A), aspartic acid (R241D), leucine (R241L), glutamine (R241Q). or tyrosine (R241Y);
(bb) the alanine residue at a position corresponding to position 242 of wild-type human Neu2 is substituted by cysteine (A242C), phenylalanine (A242F), glycine (A242G), histidine (A242H), isoleucine (A242I), lysine (A242K), leucine (A242L), methionine (A242M), asparagine (A242N), glutamine (A242Q), arginine (A242R), serine (A242S), valine (A242V), tryptophan (A242W), or tyrosine (A242Y);
(cc) the valine residue at a position corresponding to position 244 of wild-type human Neu2 is substituted by isoleucine (V244I) or proline (V244P);
(dd) the threonine residue at a position corresponding to position 249 of wild-type human Neu2 is substituted by alanine (T249A);
(ee) the aspartic acid residue at a position corresponding to position 251 of wild-type human Neu2 is substituted by glycine (D251G);
(ff) the glutamic acid residue at a position corresponding to position 257 of wild-type human Neu2 is substituted by proline (E257P);
(gg) the serine residue at a position corresponding to position 258 is substituted by cysteine (S258C);
(hh) the leucine residue at a position corresponding to position 260 of wild-type human Neu2 is substituted by aspartic acid (L260D), phenylalanine (L260F), glutamine (L260Q), or threonine (L260T);
(ii) the valine residue at a position corresponding to position 265 of wild-type human Neu2 is substituted by phenylalanine (V265F);
(jj) the glutamine residue at a position corresponding to position 270 of wild-type human Neu2 is substituted by alanine (Q270A), histidine (Q270H), phenylalanine (Q270F), proline (Q270P), serine (Q270S), or threonine (Q270T);
(kk) the tryptophan residue at a position corresponding to position 292 of wild-type human Neu2 is substituted by arginine (W292R);
(ll) the serine residue at a position corresponding to position 301 of wild-type human Neu2 is substituted by alanine (S301A), aspartic acid (S301D), glutamic acid (S301E), phenylalanine (S301F), histidine (S301H), lysine (S301K), leucine (S301L), methionine (S301M), asparagine (S301N), proline (S301P), glutamine (S301Q), arginine (S301R), threonine (S301T), valine (S301V), tryptophan (S301W), or tyrosine (S301Y);
(mm) the tryptophan residue at a position corresponding to position 302 of wild-type human Neu2 is substituted by alanine (W302A), aspartic acid (W302D), phenylalanine (W302F), glycine (W302G), histidine (W302H), isoleucine (W302I), lysine (W302K), leucine (W302L), methionine (W302M), asparagine (W302N), proline (W302P), glutamine (W302Q), arginine (W302R), serine (W302S), threonine (W302T), valine (W302V), or tyrosine (W302Y);
(nn) the valine residue at a position corresponding to position 363 of wild-type human Neu2 is substituted by arginine (V363R); or
(oo) the leucine residue at a position corresponding to position 365 of wild-type human Neu2 is substituted by glutamine (L365Q), histidine (L365H), isoleucine (L365I), lysine (L365K) or serine (L365S);
or the sialidase comprises a combination of any of the foregoing substitutions.

### Claim 13 (depends on 11, 12)

The enzyme of claim 11 or 12, wherein the sialidase comprises a substitution selected from the K9D, A42R, P62G, P62N, P62S, P62T, A93E, Q126Y, A242F, A242W, A242Y, Q270A, Q270T, S301A, S301R, W302K, W302R, V363R, and L365I substitutions, or a combination of any of the foregoing substitutions.

### Claim 14 (depends on 11, 12)

The enzyme of claim 11 or 12, wherein the sialidase comprises a substitution selected from the K9D, P62G, P62N, P62S, P62T, A93E, Q126Y, A242F, A242W, A242Y, Q270A, Q270T, S301A, S301R, W302K, W302R, V363R, and L365I substitutions, or a combination of any of the foregoing substitutions.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The enzyme of any one of claims 1-14, wherein the sialidase further comprises:
(a) a substitution or deletion of a methionine residue at a position corresponding to position 1 of wild-type human Neu2 (M1);
(b) a substitution of a valine residue at a position corresponding to position 6 of wild-type human Neu2 (V6);
(c) a substitution of an isoleucine residue at a position corresponding to position 187 of wild-type human Neu2 (I187); or
(d) a substitution of a cysteine residue at a position corresponding to position 332 of wild-type human Neu2 (C332);
or a combination of any of the foregoing substitutions.

### Claim 16 (depends on 15)

The enzyme of claim 15, wherein, in the sialidase:
(a) the methionine residue at a position corresponding to position 1 of wild-type human Neu2 is deleted (ΔM1), is substituted by alanine (M1A), or is substituted by aspartic acid (M1D);
(b) the valine residue at a position corresponding to position 6 of wild-type human Neu2 is substituted by tyrosine (V6Y);
(c) the isoleucine residue at a position corresponding to position 187 of wild-type human Neu2 is substituted by lysine (I187K); or
(d) the cysteine residue at a position corresponding to position 332 of wild-type human Neu2 is substituted by alanine (C332A);
or the sialidase comprises a combination of any of the foregoing substitutions.

### Claim 17 (depends on 16)

The enzyme of claim 16, wherein the sialidase comprises:
(a) the M1D, V6Y, P62G, A93E, I187K, and C332A substitutions;
(b) the M1D, V6Y, K9D, A93E, I187K, C332A, V363R, and L365I substitutions;
(c) the M1D, V6Y, P62N, I187K, and C332A substitutions;
(d) the M1D, V6Y, I187K, Q270A, S301R, W302K, and C332A substitutions;
(e) the M1D, V6Y, P62S, I187K, Q270A, S301R, W302K, and C332A substitutions;
(f) the M1D, V6Y, P62T, I187K, Q270A, S301R, W302K, and C332A substitutions;
(g) the M1D, V6Y, P62N, I187K, Q270A, S301R, W302K, and C332A substitutions;
(h) the M1D, V6Y, P62G, A93E, I187K, S301A, W302R, and C332A substitutions;
(i) the M1D, V6Y, P62G, A93E, Q126Y, I187K, Q270T, and C332A substitutions;
(j) the M1D, V6Y, P62G, A93E, Q126Y, I187K, and C332A substitutions;
(k) the M1D, V6Y, P62G, A93E, Q126Y, I187K, A242F, Q270T, and C332A substitutions; or
(l) the M1D, V6Y, A42R, P62G, A93E, Q126Y, I187K, A242F, Q270T, and C332A substitutions.

### Claim 18 (depends on 16)

The enzyme of claim 16, wherein the sialidase comprises:
(a) the M1D, V6Y, P62G, A93E, I187K, and C332A substitutions;
(b) the M1D, V6Y, K9D, A93E, I187K, C332A, V363R, and L365I substitutions;
(c) the M1D, V6Y, P62N, I187K, and C332A substitutions;
(d) the M1D, V6Y, I187K, Q270A, S301R, W302K, and C332A substitutions;
(e) the M1D, V6Y, P62S, I187K, Q270A, S301R, W302K, and C332A substitutions;
(f) the M1D, V6Y, P62T, I187K, Q270A, S301R, W302K, and C332A substitutions;
(g) the M1D, V6Y, P62N, I187K, Q270A, S301R, W302K, and C332A substitutions;
(h) the M1D, V6Y, P62G, A93E, I187K, S301A, W302R, and C332A substitutions;
(i) the M1D, V6Y, P62G, A93E, Q126Y, I187K, Q270T, and C332A substitutions; or
(j) the M1D, V6Y, P62G, A93E, Q126Y, I187K, A242F, Q270T, and C332A substitutions.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The enzyme of any one of claims 1-18, wherein the sialidase is selected from Neu1, Neu2, Neu3, and Neu4.

### Claim 20 (depends on 19)

The enzyme of claim 19, wherein the sialidase is Neu2.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The enzyme of any one of claims 1-20, wherein the sialidase has a different substrate specificity than the corresponding wild-type sialidase.

### Claim 22 (depends on 21)

The enzyme of claim 21, wherein the sialidase can cleave α2,3, α2,6, and/or α2,8 linkages.

### Claim 23 (depends on 22)

The enzyme of claim 22, wherein the sialidase can cleave α2,3 and α2,8 linkages.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The enzyme of any one of claims 1-23, wherein the sialidase comprises any one of SEQ ID NOs: 48-54, 149, 154, 159, 191, or 198.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The enzyme of any one of claims 1-23, wherein the sialidase comprises any one of SEQ ID NOs: 48-54, 149, 154, or 159.

### Claim 26

A recombinant mutant human sialidase comprising a mutation or combination of mutations set forth in any one of TABLES 1, 2, 7-9, 11-13, 15-30, 34, or 35, and optionally further comprising a mutation or combination of mutations set forth in any one of TABLES 3-6.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

A fusion protein comprising:
(a) the recombinant enzyme of any one of claims 1-26; and
(b) an immunoglobulin Fc domain and/or an immunoglobulin antigen-binding domain;
wherein the enzyme and the immunoglobulin Fc domain and/or the immunoglobulin antigen-binding domain are linked by a peptide bond or an amino acid linker.

### Claim 28 (depends on 27)

The fusion protein of claim 27, wherein the fusion protein comprises an immunoglobulin Fc domain.

### Claim 29 (depends on 28)

The fusion protein of claim 28, wherein the immunoglobulin Fc domain is derived from a human IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, IgD, IgE, or IgM Fc domain.

### Claim 30 (depends on 29)

The fusion protein of claim 29, wherein the immunoglobulin Fc domain is derived from a human IgG1, IgG2, IgG3, or IgG4 Fc domain.

### Claim 31 (depends on 30)

The fusion protein of claim 30, wherein the immunoglobulin Fc domain is derived from a human IgG1 Fc domain.

### Claim 32 (depends on 27, 28, 29, 30, 31)

The fusion protein of any one of claims 27-31, wherein the fusion protein comprises an immunoglobulin antigen-binding domain.

### Claim 33 (depends on 32)

The fusion protein of claim 32, wherein the immunoglobulin antigen-binding domain is associated with a second immunoglobulin antigen-binding domain to produce an antigen-binding site.

### Claim 34 (depends on 32, 33)

The fusion protein of claim 32 or 33, wherein the immunoglobulin antigen-binding domain is derived from an antibody selected from trastuzumab, daratumumab, girentuximab, ofatumumab, avelumab, and rituximab.

### Claim 35 (depends on 27, 28, 29, 30, 31, 32, 33, 34)

The fusion protein of any one of claims 27-34, wherein the fusion protein comprises any one of SEQ ID NOs: 203-210, 218, 220, 222, 224, 226, 228, 230, 232, 234, 236, 238, 240, or 242

### Claim 36 (depends on 27, 28, 29, 30, 31, 32, 33, 34, 35)

An antibody conjugate comprising the fusion protein of any one of claims 27-35.

### Claim 37 (depends on 36)

The antibody conjugate of claim 36, wherein the antibody conjugate comprises a single sialidase.

### Claim 38 (depends on 36)

The antibody conjugate of claim 36, wherein the antibody conjugate comprises two sialidases.

### Claim 39 (depends on 37)

The antibody conjugate of claim 37, wherein the two sialidases are identical.

### Claim 40 (depends on 36, 37, 38, 39)

The antibody conjugate of any one of claims 36-39, wherein the antibody conjugate comprises a single antigen-binding site.

### Claim 41 (depends on 36, 37, 38, 39)

The antibody conjugate of any one of claims 36-39, wherein the antibody conjugate comprises two antigen-binding sites.

### Claim 42 (depends on 41)

The antibody conjugate of claim 41, wherein the two antigen-binding sites are identical.

### Claim 43 (depends on 36, 37, 38, 39, 40, 41, 42)

The antibody conjugate of any one of claims 36-42, wherein the antibody conjugate has a molecular weight from about 135 kDa to about 165 kDa.

### Claim 44 (depends on 36, 37, 38, 39, 40, 41, 42)

The antibody conjugate of any one of claims 36-42, wherein the antibody conjugate has a molecular weight from about 215 kDa to about 245 kDa.

### Claim 45 (depends on 36, 37, 38, 39, 40, 41, 42, 43, 44)

The antibody conjugate of any one of claims 36-44, wherein the antibody conjugate comprises:
(a) a first polypeptide comprising an immunoglobulin light chain;
(b) a second polypeptide comprising an immunoglobulin heavy chain; and
(c) a third polypeptide comprising an immunoglobulin Fc domain and a sialidase;
wherein the first and second polypeptides are covalently linked together and the second and third polypeptides are linked together, and wherein the first polypeptide and the second polypeptide together define an antigen-binding site.

### Claim 46 (depends on 45)

The antibody conjugate of claim 45, wherein the third polypeptide comprises the sialidase and the immunoglobulin Fc domain in an N- to C-terminal orientation.

### Claim 47 (depends on 36, 37, 38, 39, 40, 41, 42, 43, 44)

The antibody conjugate of any one of claims 36-44, wherein the fusion protein comprises:
(a) a first polypeptide comprising a first immunoglobulin light chain;
(b) a second polypeptide comprising a first immunoglobulin heavy chain and a first sialidase;
(c) a third polypeptide comprising a second immunoglobulin heavy chain and a second sialidase; and
(d) a fourth polypeptide comprising a second immunoglobulin light chain;
wherein the first and second polypeptides are covalently linked together, the third and fourth polypeptides are covalently linked together, and the second and third polypeptides are covalently linked together, and wherein the first polypeptide and the second polypeptide together define a first antigen-binding site, and the third polypeptide and the fourth polypeptide together define a second antigen-binding site.

### Claim 48 (depends on 47)

The antibody conjugate of claim 47, wherein the second and third polypeptides comprise the first and second immunoglobulin heavy chain and the first and second sialidase, respectively, in an N- to C-terminal orientation.

### Claim 49 (depends on 36, 37, 38, 39, 40, 41, 42, 43, 44)

The antibody conjugate of any one of claims 36-44, wherein the antibody conjugate comprises:
(a) a first polypeptide comprising a first sialidase, a first immunoglobulin Fc domain, and a first single chain variable fragment (scFv); and
(b) a second polypeptide comprising a second sialidase, a second immunoglobulin Fc domain, and a second single chain variable fragment (scFv);
wherein the first and second polypeptides are covalently linked together, and wherein the first scFv defines a first antigen-binding site, and the second scFv defines a second antigen-binding site.

### Claim 50 (depends on 49)

The antibody conjugate of claim 49, wherein the first polypeptide comprises the first sialidase, the first immunoglobulin Fc domain, and the first scFv in an N- to C-terminal orientation, and the second polypeptide comprises the second sialidase, the second immunoglobulin Fc domain, and the second scFv in an N- to C-terminal orientation.

### Claim 51 (depends on 36, 37, 38, 39, 40, 41, 42, 43, 44)

The antibody conjugate of any one of claims 36-44, wherein the antibody conjugate comprises:
(a) a first polypeptide comprising an immunoglobulin light chain;
(b) a second polypeptide comprising an immunoglobulin heavy chain and a single chain variable fragment (scFv); and
(c) a third polypeptide comprising an immunoglobulin Fc domain and a sialidase;
wherein the first and second polypeptides are covalently linked together and the second and third polypeptides are covalently linked together, and wherein the immunoglobulin light chain and immunoglobulin heavy chain together define a first antigen-binding site and the scFv defines a second antigen-binding site.

### Claim 52 (depends on 51)

The antibody conjugate of claim 51, wherein the second polypeptide comprises the immunoglobulin heavy chain and the scFv in an N- to C-terminal orientation, and the third polypeptide comprises the sialidase and the immunoglobulin Fc domain in an N- to C-terminal orientation.

### Claim 53 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

An isolated nucleic acid comprising a nucleotide sequence encoding the recombinant enzyme of any one of claims 1-26, the fusion protein of any one of claims 27-35, or at least a portion of the antibody conjugate of any one of claims 36-52.

### Claim 54 (depends on 53)

An expression vector comprising the nucleic acid of claim 53.

### Claim 55 (depends on 54)

A host cell comprising the expression vector of claim 54.

### Claim 56 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

A pharmaceutical composition comprising the recombinant enzyme of any one of claims 1-26, the fusion protein of any one of claims 27-35, or the antibody conjugate of any one of claims 36-52.

### Claim 57 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 56)

A method of treating cancer in a subject in need thereof, the method comprising administering to the subject an effective amount of the recombinant enzyme of any one of claims 1-26, the fusion protein of any one of claims 27-35, or at least a portion of the antibody conjugate of any one of claims 36-52, or the pharmaceutical composition of claim 56.

### Claim 58 (depends on 57)

The method of claim 57, wherein the cancer is a solid tumor, soft tissue tumor, hematopoietic tumor or metastatic lesion.

### Claim 59 (depends on 58)

The method of claim 58, wherein the solid tumor is a sarcoma, adenocarcinoma, or carcinoma.

### Claim 60 (depends on 58, 59)

The method of claim 58 or 59, wherein the solid tumor is a head and neck (e.g., pharynx), thyroid, lung (e.g., small cell or non-small cell lung carcinoma (NSCLC)), breast, lymphoid, gastrointestinal (e.g., oral, esophageal, stomach, liver, pancreas, small intestine, colon and rectum, anal canal), genital or genitourinary tract (e.g., renal, urothelial, bladder, ovarian, uterine, cervical, endometrial, prostate, testicular), CNS (e.g., neural or glial cell, e.g., neuroblastoma or glioma), or skin (e.g., melanoma) tumor.

### Claim 61 (depends on 58)

The method of claim 58, wherein the hematopoietic tumor is a leukemia, acute leukemia, acute lymphoblastic leukemia (ALL), B-cell, T-cell or FAB ALL, acute myeloid leukemia (AML), chronic myelocytic leukemia (CIVIL), chronic lymphocytic leukemia (CLL), e.g., transformed CLL, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, hairy cell leukemia, myelodyplastic syndrome (MDS), lymphoma, Hodgkin's disease, malignant lymphoma, non-Hodgkin's lymphoma, Burkitt's lymphoma, multiple myeloma, or Richter's Syndrome (Richter's Transformation).
